[CASI] CASI Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.24 Change: 0.03 (2.48%)
Ext. hours: Change: 0 (0%)

chart CASI

Refresh chart

Strongest Trends Summary For CASI

CASI is in the long-term up 249% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company?s lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Fundamental Ratios
Shares Outstanding EPS-0.17 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-5.41
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-260.69% ROE1454.22% ROI
Current Ratio3.84 Quick Ratio Long Term Debt/Equity Debt Ratio-1.41
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities-1.21 M Gross Profit20 K
Net Profit-1.8 M Operating Profit-1.77 M Total Assets10.19 M Total Current Assets9.91 M
Total Current Liabilities2.58 M Total Debt1.41 M Total Liabilities12.01 M Total Revenue20 K
Technical Data
High 52 week8.23 Low 52 week2.77 Last close3.39 Last change0.3%
RSI24.77 Average true range0.23 Beta0.8 Volume47.53 K
Simple moving average 20 days-6.68% Simple moving average 50 days-13.64% Simple moving average 200 days-38.88%
Performance Data
Performance Week0.89% Performance Month-16.71% Performance Quart-2.59% Performance Half-53.75%
Performance Year-15.25% Performance Year-to-date-15.67% Volatility daily2.65% Volatility weekly5.93%
Volatility monthly12.15% Volatility yearly42.1% Relative Volume117.8% Average Volume352.03 K
New High New Low

News

2019-08-20 19:15:15 | Casi Pharmaceuticals Inc CASI CEO Wei-wu He Bought $64,000 of Shares

2019-08-19 12:22:11 | What Kind Of Shareholders Own CASI Pharmaceuticals, Inc. NASDAQ:CASI?

2019-08-16 10:20:00 | CASI: CASI launches Evomela - first commercial product

2019-08-15 19:15:09 | Casi Pharmaceuticals Inc CASI CEO Wei-wu He Bought $507,200 of Shares

2019-08-12 15:03:45 | Rockville biopharma to sell first product on market in 28 years — but not in the U.S.

2019-08-12 07:00:00 | CASI Pharmaceuticals Announces Launch of EVOMELA® melphalan for injection in China

2019-08-09 07:00:00 | CASI Pharmaceuticals Announces Second Quarter and First Half 2019 Financial and Business Results

2019-07-31 10:44:02 | Ligand LGND Stock Down Despite Q2 Earnings & Sales Beat

2019-06-17 07:00:00 | CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy

2019-06-03 07:00:00 | CASI Pharmaceuticals To Present At The 2019 BIO International Convention

2019-05-20 09:45:00 | CASI: Making headway towards commercialization

2019-05-15 07:00:00 | CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results

2019-05-13 10:00:00 | CASI: Initiating coverage – Leveraging pharmaceutical opportunities in China and beyond

2019-05-03 08:42:12 | Ligand LGND Q1 Earnings & Sales Fall Y/Y, Stock Down

2019-04-18 16:15:00 | INVESTOR ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers

2019-04-17 07:00:00 | CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics

2019-04-02 07:00:00 | CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer

2019-03-29 07:00:00 | CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results And Business Results

2019-03-13 07:00:00 | CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection EVOMELA® In China

2019-03-07 07:00:00 | CASI Pharmaceuticals Announces China National Medical Products Administration NMPA Approval Of CTA To Conduct Registration Trial For MARQIBO®

2019-02-26 08:14:52 | When Will CASI Pharmaceuticals, Inc. NASDAQ:CASI Turn A Profit?

2019-02-20 08:15:00 | Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI Pharmaceuticals, Ellie Mae, and Douglas Emmett — Future Expectations, Projections Moving into 2019

2019-02-19 07:00:00 | CASI Pharmaceuticals Announces China National Medical Products Administration NMPA Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®

2019-02-06 07:00:00 | CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference

2018-12-28 11:45:00 | These 4 Healthcare Stocks Are Heating Up

2018-12-26 09:32:45 | Do Institutions Own Shares In CASI Pharmaceuticals, Inc. NASDAQ:CASI?

2018-12-03 09:15:00 | The 4 Healthcare Stocks To Watch On Monday

2018-12-03 08:12:00 | CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection Trademark: EVOMELA®

2018-11-30 16:05:00 | Chinese biotech stocks hit by a double whammy, which means it’s time to buy

2018-11-28 08:40:00 | Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments

2018-11-16 07:00:00 | CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China

2018-11-14 07:00:00 | CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results

2018-10-24 08:00:00 | Today’s Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences

2018-10-23 15:47:00 | Why CASI Pharmaceuticals Inc. Is Rocketing Higher Today

2018-10-23 14:30:00 | 3 Healthcare Stocks Trending Higher On News

2018-10-23 07:05:00 | CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited

2018-10-18 08:40:00 | Detailed Research: Economic Perspectives on Beacon Roofing Supply, Rowan Companies, CASI Pharmaceuticals, LivePerson, Impinj, and Tredegar — What Drives Growth in Today's Competitive Landscape

2018-10-02 07:00:00 | CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization

2018-09-28 07:00:00 | CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer

2018-09-14 07:00:00 | CASI Pharmaceuticals Announces $48.5 Million Private Placement

2018-08-27 08:20:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Steelcase, SecureWorks, Cleveland-Cliffs, Tredegar, Warrior Met Coal, and CASI Pharmaceuticals — New Research Emphasizes Economic Growth

2018-08-14 07:00:00 | CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results

2018-07-05 07:43:12 | Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index

2018-07-03 13:05:00 | CASI Pharmaceuticals Added To Russell 2000®, 3000® And Microcap® Indexes

2018-06-25 08:00:00 | Report: Exploring Fundamental Drivers Behind Cabot Oil & Gas, Chesapeake Lodging Trust, CASI Pharmaceuticals, Peabody Energy, Alcoa, and Edwards Lifesciences — New Horizons, Emerging Trends, and Upcoming Developments

2018-06-21 16:14:00 | Here's Why CASI Pharmaceuticals Rose as Much as 31.6% Today

2018-06-21 07:00:00 | CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol

2018-05-31 08:30:00 | Free Technical Insights on CASI Pharma and Three Other Biotech Stocks

2018-05-29 07:00:00 | CASI Pharmaceuticals To Present At The BIO International Convention

2018-05-15 07:00:00 | CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results